Hepion Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Apr 8, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 8, 2025
HEPA$0.11-13.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Preferred Stock Series A · Preferred Stock Series C · Common Stock · Additional Paid in · Accumulated Other Comprehensive · Accumulated · Total Stockholders’ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance at December 31, 2022 | 85,581 | 855,808 | 1,801 | 840,320 | 76,230 | 8 | 223,951,313 | (90,168) | (175,701,344) | 49,855,937 |
| Net loss | — | — | — | — | — | — | — | — | (48,926,042) | (48,926,042) |
| Other comprehensive loss | — | — | — | — | — | — | — | 11,389 | — | 11,389 |
| Stock-based compensation expense | — | — | — | — | — | — | 1,340,311 | — | — | 1,340,311 |
| Stock-based liability awards converted to equity | — | — | — | — | — | — | 2,983,006 | — | — | 2,983,006 |
| Issuance of common stock in connection with stock split | — | — | — | — | 536 | — | — | — | — | — |
| Conversion of preferred stock to common | — | — | (113) | (1,000) | 1 | — | 1,000 | — | — | — |
| Issuance of common stock, net | — | — | — | — | 8,000 | 1 | 39 | — | — | 40 |
| Warrant exercises | — | — | — | — | 11,608 | 1 | 2,016,165 | — | — | 2,016,166 |
| Balance at December 31, 2023 | 85,581 | $855,808 | 1,688 | $839,320 | 96,375 | $10 | $230,291,834 | $(78,779) | $(224,627,386) | $7,280,807 |
| Net loss | — | — | — | — | — | — | — | — | (13,192,420) | (13,192,420) |
| Other comprehensive income/loss | — | — | — | — | — | — | — | 87,124 | — | 87,124 |
| Stock-based compensation expense | — | — | — | — | — | — | 791,645 | — | — | 791,645 |
| Warrant exercises, net | — | — | — | — | 13,088 | 1 | 2,300,688 | — | — | 2,300,689 |
| Issuance of shares in abeyance | — | — | — | — | 6,520 | 1— | (1) | — | — | — |
| Issuance of common stock | — | — | — | — | 23,185 | 2 | 868,815 | — | — | 868,817 |
| Balance at December 31, 2024 | 85,581 | $855,808 | 1,688 | $839,320 | 139,168 | $14 | $234,252,981 | $8,345 | $(237,819,806) | $(1,863,338) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.